VCTX210 (Vertex collab.)
Type 1 Diabetes
Phase 1/2Clinical
Key Facts
About CRISPR Therapeutics
CRISPR Therapeutics is a pioneering biopharmaceutical company dedicated to discovering, developing, and commercializing curative gene-editing treatments. Founded by CRISPR gene-editing pioneers, the company leverages its proprietary CRISPR/Cas9 platform to create a diverse pipeline targeting hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo diseases. Its landmark achievement is the approval of CASGEVY, the world's first CRISPR/Cas9 gene-edited therapy, marking a new era in medicine and validating its platform's potential. The company collaborates with Vertex Pharmaceuticals and Bayer to accelerate development and commercialization across multiple therapeutic areas.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| VX-880 | Vertex Pharmaceuticals | Phase 1/2 |
| UP421 | Sana Biotechnology | Pre-Clinical |
| SC451 | Sana Biotechnology | Pre-Clinical |
| BioVascular Pancreas™ | Humacyte | Preclinical |
| ORMD-0801 | Oramed Pharmaceuticals | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |